Skip to main content
Equibles

Stacey Koo

Analyst

TD Cowen

Equibles does not estimate personal net worth.

About Stacey Koo

Stacey Koo is recorded as Analyst at TD Cowen. Stacey Koo has spoken on 4 earnings calls across 4 companies, most recently for DiaMedica Therapeutics Inc. on August 11, 2026. Those appearances were for DiaMedica Therapeutics Inc. (DMAC), LENZ Therapeutics, Inc. (LENZ), Biocryst Pharmaceuticals Inc (BCRX) and Supernus Pharmaceuticals, Inc. (SUPN). The companies whose calls Stacey Koo spoke on are classified in the Healthcare sector.

Stacey Koo on recent calls

“So first, on the fetal growth restriction, let's say cohort one data that we're going to get in September, maybe just help us understand the importance of maybe that chronic dosing that we're going to see.”
Analyst — TD Cowen, Second Quarter 2026 Financial Results Conference Call ·
“First is on the refill dynamics, where we appreciate you giving us this level of detail, but maybe put it in the context of other presbyopia, eye drop products.”
Analyst — TD Cowen, LENZ Therapeutics, Inc. Q2 FY2026 Earnings Call ·
“So first, as we think about Oralodeo, maybe just can you talk through the clinician additions this quarter versus historical averages? What kind of halo effect might you expect with the pediatric launch?”
Analyst — TD Cowen, BioCryst Second Quarter 2026 Earnings Call ·
“So first, just as we think about the ANAPCO guidance for the year and the patient demand that clearly all the analysts are trying to triangulate around, maybe first, could you talk about the learnings on the patient profile since launch?”
Analyst — TD Cowen, Supernus Pharmaceuticals, Inc. Q4 FY2025 Earnings Call ·

Affiliation history

  • TD Cowen

    Analyst

    Transcript header (unverified)

    Current

Company network

Recent activity